Peripheral effects of morphine and expression of μ-opioid receptors in the dorsal root ganglia during neuropathic pain : nitric oxide signaling by Hervera Abad, Arnau et al.
RESEARCH Open Access
Peripheral effects of morphine and expression of
μ-opioid receptors in the dorsal root ganglia
during neuropathic pain: nitric oxide signaling
Arnau Hervera1, Roger Negrete1, Sergi Leánez1, Jesús M Martín-Campos2 and Olga Pol1*
Abstract
Background: The local administration of μ-opioid receptor (MOR) agonists attenuates neuropathic pain but the
precise mechanism implicated in this effect is not completely elucidated. We investigated if nitric oxide synthesized
by neuronal (NOS1) or inducible (NOS2) nitric oxide synthases could modulate the local antiallodynic effects of
morphine through the peripheral nitric oxide-cGMP-protein kinase G (PKG)-ATP-sensitive K+ (KATP) channels
signaling pathway activation and affect the dorsal root ganglia MOR expression during neuropathic pain.
Results: In wild type (WT) mice, the subplantar administration of morphine dose-dependently decreased the
mechanical and thermal allodynia induced by the chronic constriction of the sciatic nerve (CCI), which effects were
significantly diminished after their co-administration with different subanalgesic doses of a selective NOS1 (N-[(4S)-
4-amino-5-[(2-aminoethyl)amino]pentyl]-N’-nitroguanidine tris(trifluoroacetate) salt; NANT), NOS2 (L-N(6)-(1-
iminoethyl)-lysine; L-NIL), L-guanylate cyclase (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; ODQ), PKG ((Rp)-8-(para-
chlorophenylthio)guanosine-3’,5’-cyclic monophosphorothioate; Rp-8-pCPT-cGMPs) inhibitor or a KATP channel
blocker (glibenclamide). The evaluation of the expression of MOR in the dorsal root ganglia from sham-operated
and sciatic nerve-injured WT, NOS1 knockout (KO) and NOS2-KO mice at 21 days after surgery demonstrated that,
although the basal mRNA and protein levels of MOR were similar between WT and both NOS-KO animals, nerve
injury only decreased their expression in WT mice.
Conclusions: These results suggest that the peripheral nitric oxide-cGMP-PKG-KATP signaling pathway activation
participates in the local antiallodynic effects of morphine after sciatic nerve injury and that nitric oxide, synthesized
by NOS1 and NOS2, is implicated in the dorsal root ganglia down-regulation of MOR during neuropathic pain.
Background
Neuropathic pain is a clinical manifestation character-
ized by the presence of allodynia and hyperalgesia and it
is difficult to treat with the most potent analgesic com-
pounds. Recent studies have demonstrated that the per-
ipheral administration of μ-opioid receptor (MOR)
agonists elicits antinociception in different models of
neuropathic pain [1,2] and that their expression
decreases after nerve injury [2,3]. Even so, the precise
mechanisms implicated in the peripheral actions of
morphine as well as in the expression of MOR during
neuropathic pain are not completely elucidated.
Several studies have shown that nitric oxide, synthe-
sized by neuronal (NOS1) or inducible (NOS2) nitric
oxide synthases, mediates numerous neuropathic pain
symptoms via central and peripheral nitric oxide-cGMP-
PKG pathway activation [4-6]. Accordingly, the expres-
sion of NOS1 and NOS2 is up-regulated in the spinal
cord and dorsal root ganglia of animals with neuro-
pathic pain [7,8]. Moreover, the mechanical and thermal
allodynia induced by nerve injury was reversed by the
administration of selective NOS, guanylate cyclase o
PKG inhibitors and attenuated or abolished in NOS1
and NOS2 knockout (KO) animals [4,6,8-10].
It is well known that the peripheral nitric oxide-
cGMP-protein kinase G (PKG)-ATP-sensitive K+
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(KATP) channels signaling pathway activation plays a
critical role in the local antinociceptive effects of mor-
phine during inflammatory pain [11-13] but not in the
peripheral antinociceptive effects of δ-opioid receptor
(DOR) agonists during neuropathic pain [6]. In addition,
several studies also show that nitric oxide regulates the
expression of MOR and DOR under several pain condi-
tions [6,14,15] but the exact role of nitric oxide in the
peripheral antinociceptive actions of morphine and
expression of MOR during neuropathic pain is not
known.
Thus, to study if the nitric oxide-cGMP-PKG-KATP
peripheral pathway activation, triggered by NOS1 and
NOS2, could modulate the local effects of morphine in
nerve-injured wild type (WT) mice, at 21 days after the
chronic constriction of the sciatic nerve (CCI), we evalu-
ated: 1) the mechanical and thermal antiallodynic effects
of the subplantar administration of morphine; 2) the
reversibility of these effects by their local co-administra-
tion with a selective MOR antagonist, D-Phe-Cys-Tyr-
D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP) or a peripheral
non-selective opioid receptor antagonist, naloxone
methiodide (NX-ME); 3) the mechanical and thermal
antiallodynic effects of a high dose of morphine co-
administered with different subanalgesic doses of a
selective NOS1 (N-[(4S)-4-amino-5-[(2-aminoethyl)
amino]pentyl]-N’-nitroguanidine tris(trifluoroacetate)
salt; NANT), NOS2 (L-N(6)-(1-iminoethyl)-lysine; L-
NIL), soluble guanylate cyclase (1H-[1,2,4]oxadiazolo
[4,3-a]quinoxalin-1-one; ODQ), PKG ((Rp)-8-(para-
chlorophenylthio)guanosine-3’,5’-cyclic monophosphor-
othioate; Rp-8-pCPT-cGMPs) inhibitor or a KATP
channel blocker (glibenclamide).
To evaluate the role played by nitric oxide, synthe-
sized by NOS1 and NOS2, in the peripheral expression
of MOR during neuropathic pain, the mRNA and pro-
tein levels of MOR in the dorsal root ganglia of sciatic
nerve-injured WT, NOS1-KO and NOS2-KO mice, at
21 days after surgery, were also assessed.
Results
Expression of neuropathic pain in WT mice
In accordance to our previous reports [6,8], the total
sciatic nerve ligation produced unilateral mechanical
allodynia and thermal allodynia at 21 days after surgery.
Thus, sciatic nerve injury led to a significant decrease in
the percentage of the basal response of the threshold for
evoking paw withdrawal to a mechanical stimulus in the
ipsilateral paw of sciatic nerve-injured animals (37.4 ±
3.5) as compared to their contralateral paw (100.0 ± 6.3)
as well as to the contralateral (104.5 ± 4.7) and ipsilat-
eral (93.5 ± 9.1) paws of sham-operated mice (P <
0.001; one-way ANOVA followed by the Student New-
man Keuls test). Similar results has been obtained for
thermal allodynia where a significant increase in the
number of paw elevations to cold thermal stimulus in
the ipsilateral paw of sciatic nerve-injured animals (5.7
± 0.6) as compared to their contralateral paw (0.2 ± 0.2)
as well as to the contralateral (0.3 ± 0.2) and ipsilateral
(0.2 ± 0.2) paws of sham-operated mice, has been also
demonstrated (P < 0.001; one-way ANOVA followed by
the Student Newman Keuls test).
Effects of the subplantar administration of morphine in
the mechanical and thermal allodynia induced by sciatic
nerve injury in WT mice and reversal of their effects by
CTAP or NX-ME
The subplantar administration of morphine into the
ipsilateral paw dose-dependently inhibited the mechani-
cal (Figure 1A) and thermal (Figure 1B) allodynia
induced by the chronic constriction of the sciatic nerve.
Thus, the mechanical and thermal antiallodynic effects
produced by high doses of morphine in the ipsilateral
paw of sciatic nerve-injured WT mice were significantly
higher than those obtained in their corresponding vehi-
cle treated groups (P <0.05; Student’s t test). Moreover,
analyzing the ED50 values our data showed that the
potency of morphine on the inhibition of mechanical,
194.9 nmol (148.7-255.9) and thermal sensitivity, 225.9
nmol (191.0-267.1) induced by sciatic nerve injury was
very analogous.
The subplantar administration of morphine or vehicle
did not elicit any significant antinociceptive effect
neither in the contralateral paw of sciatic nerve-injured
mice nor in the ipsilateral or contralateral paw of sham-
operated mice (data not shown).
The mechanical (Figure 2A) and thermal (Figure 2B)
antiallodynic effects produced by morphine (400 nmol)
in the ipsilateral paw of sciatic nerve-injured WT mice
were completely reversed by the subplantar co-adminis-
tration with a selective MOR (CTAP, 108.7 nmol) or the
non-selective peripherally acting opioid receptor (NX-
ME, 42.6 nmol) antagonist (P <0.001; one way ANOVA
followed by the Student Newman Keuls test). The sub-
plantar administration of vehicle, CTAP or NX-ME
alone in sciatic nerve-injured and sham-operated WT
mice did not show any significant effect on the two dif-
ferent nociceptive responses evaluated in this study.
Involvement of the peripheral nitric oxide-cGMP-PKG-
KATP signaling pathway triggered by NOS1 and NOS2 in
local antiallodynic effects produced by morphine after
the sciatic nerve injury in WT mice
The role of the peripheral nitric oxide-cGMP-PKG-
KATP signaling pathway, activated by NOS1 and NOS2,
in the local mechanical and thermal antiallodynic effects
produced by morphine during neuropathic pain was
assessed by evaluating the effects produced by a high
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dose of morphine (400 nmol) co-administered with dif-
ferent dose of NANT, L-NIL, ODQ, Rp-8-pCPT-
cGMPs, glibenclamide or vehicle in sciatic nerve-injured
WT mice at 21 days after surgery.
Our results showed that the local mechanical and
thermal antiallodynic effects of morphine in the ipsilat-
eral paw of sciatic nerve-injured WT mice were
inhibited by their peripheral co-administration with
NANT or L-NIL (Figure 3) as well as with ODQ, Rp-8-
pCPT-cGMPs or glibenclamide (Figure 4) in a dose-
dependent manner (P <0.001, one way ANOVA fol-
lowed by Student Newman Keuls test). Moreover, the
local co-administration of morphine plus NANT, L-NIL,
ODQ, Rp-8-pCPT-cGMPs or glibenclamide did not
have any significant effect neither on the contralateral
paw of sciatic nerve-injured mice nor in the ipsilateral
or contralateral paw of sham-operated animals (data not
shown).
Figure 1 Antiallodynic effects of morphine . Effects of the
subplantar administration of different doses (logarithmic axis) of
morphine or vehicle on the mechanical (A) and thermal allodynia
(B) induced by CCI in the ipsilateral paw of WT mice at 21 days
after surgery. Morphine was administered 20 min before starting
behavioral testing. Data are expressed as mean values of maximal
possible effect (%) for mechanical allodynia and inhibition (%) for
thermal allodynia ± SEM (5-6 animals for dose). In both tests, for
each dose, * P <0.05 and *** P <0.001 denote significant differences
between morphine and vehicle treated animals (Student’s t test).
Figure 2 Reversion of the antiallodynic effects of morphine.
Reversal of the effects of morphine (400 nmol) on the mechanical
(A) and thermal (B) allodynia induced by CCI in the ipsilateral paw
of WT mice, at 21 days after CCI, by the subplantar co-
administration of a selective MOR antagonist (CTAP; 108.7 nmol) or
a peripheral non-selective opioid receptor antagonist (NX-ME; 42.6
nmol). The effects of the subplantar administration of vehicle, CTAP
(108.7 nmol) or NX-ME (42.6 nmol) administered alone are also
shown. Data are expressed as mean values of maximal possible
effect (%) for mechanical allodynia and inhibition (%) for thermal
allodynia ± SEM (5-6 animals for each group). For each test, *
represents significant differences compared to the other groups
(P <0.05; one way ANOVA, followed by the Student Newman Keuls
test).
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Our results also indicated that the subplantar adminis-
tration of the highest doses of NANT (50.9 nmol) or L-
NIL (134.1 nmol; Figure 3) as well as of ODQ (13.3
nmol), Rp-8-pCPT-cGMP (4.1 nmol) or glibenclamide
(60.7 nmol; Figure 4) administered alone did not pro-
duce any significant antiallodynic effect on the ipsilateral
paws of sciatic nerve-injured WT mice as compared to
vehicle group. Moreover, the subplantar administration
of these doses of NANT, L-NIL, ODQ, Rp-8-pCPT-
cGMPs or glibenclamide as well as of vehicle did not
have any significant antinociceptive effect neither on the
contralateral paw of sciatic nerve-injured mice nor in
the ipsilateral or contralateral paw of sham-operated
animals (data not shown).
The expression of MOR in the dorsal root ganglia of
sciatic nerve-injured WT, NOS1-KO and NOS2-KO mice
The mRNA and protein levels of MOR in the dorsal
root ganglia of WT and both NOS-KO mice are shown
in Figure 5A and 5B, respectively. Although the two way
ANOVA did not show any effect of the genotype or sur-
gery, a significant interaction between theme was
demonstrated for mRNA (P <0.037) and protein (P
<0.029) expression. Thus, while sciatic nerve injury sig-
nificantly decreases the MOR mRNA (P <0.043, Stu-
dent’s t test) and protein (Student’s t test, P <0.002)
levels in WT mice, it did not change their expression in
both KO mice when comparing sciatic nerve-injured vs.
sham-operated animals.
Figure 3 Role of the peripheral nitric oxide synthesized by NOS1 and NOS2 in the antiallodynic effects of morphine. Mechanical (A, C)
and thermal (B, D) antiallodynic effects of the subplantar co-administration of morphine (400 nmol) plus vehicle or different doses of NANT (17.0
- 50.9 nmol; A, B) or L-NIL (44.7 - 134.1 nmol; C, D) in the ipsilateral paw of sciatic nerve-injured WT mice at 21 days after surgery. The effects of
the subplantar administration of vehicle and the maximal doses of NANT (50.9 nmol) or L-NIL (134.1 nmol) injected alone are also shown. All
drugs were administered 20 min before starting behavioral testing. Data are expressed as mean values of the maximal possible effect (%) for
mechanical allodynia and as inhibition (%) for thermal allodynia ± SEM (5-6 animals per group). For each behavioral test and selective inhibitor
assayed, * P <0.05 denotes significant differences vs. group treated with morphine plus vehicle (one way ANOVA followed by Student Newman
Keuls test) and + P <0.05 denotes significant differences vs. group treated with vehicle (one way ANOVA followed by the Student Newman Keuls
test).
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Figure 4 Role of the peripheral nitric oxide-cGMP-PKG-KATP signaling pathway in the antiallodynic effects of morphine. Mechanical (A,
C, E) and thermal (B, D, F) antiallodynic effects of the subplantar co-administration of morphine (400 nmol) plus vehicle or different doses of
ODQ (4.0 - 13.3 nmol; A, B), Rp-8 (1.2 - 4.1 nmol; C, D) or glibenclamide (Glib; 20.2 - 60.7 nmol; E,F) in the ipsilateral paw of sciatic nerve-injured
WT mice at 21 days after surgery. The effects of the subplantar administration of vehicle and the maximal doses of ODQ (13.3 nmol), Rp-8 (4.1
nmol) or glibenclamide (60.7 nmol) injected alone are also shown. All drugs were administered 20 min before starting behavioral testing. Data
are expressed as mean values of the maximal possible effect (%) for mechanical allodynia and as inhibition (%) for thermal allodynia ± SEM (5-6
animals per group). For each behavioral test and selective inhibitor assayed, * P <0.05 denotes significant differences vs. group treated with
morphine plus vehicle (one way ANOVA followed by the Student Newman Keuls test) and + P <0.05 denotes significant differences vs. group
treated with vehicle (one way ANOVA followed by Student Newman Keuls test).
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In addition, non significant differences were found
between genotypes when compared the expression of
MOR mRNA among theme in sham-operated or sciatic
nerve-injured mice, although a significant increase in
the MOR protein levels were observed in sciatic nerve-
injured mice when compared NOS2-KO vs. WT animals
(one way ANOVA, P <0.014).
Discussion
The present results demonstrate for first time that the
local administration of morphine dose-dependently
inhibited the mechanical and thermal allodynia induced
by sciatic nerve injury through the activation of the per-
ipheral nitric oxide-cGMP-PKG-KATP signaling path-
way. This study also shows that nitric oxide, synthesized
by NOS1 and NOS2, is implicated in the peripheral
down-regulation of MOR during neuropathic pain.
In a model of CCI-induced neuropathic pain, our
results confirmed the mechanical antiallodynic effects of
MOR agonists locally administered [1,2] and further
demonstrated the thermal antiallodynic effects produced
by morphine in these experimental conditions with a
similar effectiveness. The specificity and the peripheral
antiallodynic effects of morphine after sciatic nerve
injury was demonstrated by the complete reversion of
their effects with a selective MOR antagonist (CTAP)
and a non-selective peripherally acting opioid receptor
antagonist (NX-ME), which did not have any effect
when were administered alone. In addition, the highest
dose of morphine did not produce any significant effect
in the contralateral paw of sciatic nerve-injured mice,
supporting the peripheral site of action of this drug.
A clear relationship between the antinociceptive
effects of MOR agonists and the peripheral nitric oxide-
cGMP-PKG-KATP signaling pathway activation during
inflammatory pain has been extensively demonstrated
[11-13,16]. Our results show for first time, that the local
administration of morphine alleviates the mechanical
and thermal allodynia induced by sciatic nerve injury
through the activation of the peripheral nitric oxide-
cGMP-PKG signaling pathway, triggered by NOS1 and
NOS2, which culminate in an increased activation of
KATP channels causing the hyperpolarization of noci-
ceptive neurons. Indeed, the local mechanical and ther-
mal antiallodynic effects produced by a high dose of
morphine in sciatic nerve-injured WT mice were dose-
dependently diminished with their co-administration
with subanalgesic doses of L-NIL, NANT, ODQ, Rp-8-
pCPT-cGMPs or glibenclamide. These results are in
contrast to the reduced nociceptive responses induced
by morphine after their intrathecal co-administration
with several nitric oxide-cGMP-PKG-MAPKs inhibitors
[17]. These findings support the idea that the nitric
oxide-cGMP pathway may play different roles depending
on the site of action, whereas peripheral activation pro-
duces antinociception, their central activation should be
causing of nociceptive behaviors [18]. In addition, while
the peripheral administration of morphine causes anti-
nociception by the activation of the peripheral nitric
oxide-cGMP signaling pathway which culminate in an
increased activation of KATP channels causing the
hyperpolarization of nociceptive neurons [13], their
Figure 5 Dorsal root ganglia expression of MOR in WT, NOS1-
KO and NOS2-KO mice. Relative mRNA (A) and protein (B)
expression of MOR in the ipsilateral dorsal root ganglia from sham-
operated or sciatic nerve-injured WT, NOS1-KO and NOS2-KO mice.
Data are expressed as mean values ± SEM (4-5 samples per group).
For each genotype, * P <0.05 denotes significant differences
between sciatic nerve-injured and sham-operated mice (Student’s t
test). For each experimental group, different letters (a, b) denote
significant differences between genotypes (P <0.05; one way
ANOVA followed by the Student Newman Keuls test).
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intrathecal administration produces nociception by the
activation of the spinal nitric oxide-cGMP signaling
pathway that culminate in an increased activation of
MAPKs which increases membrane excitability and
induces spinal neuronal sensitization [19]. Moreover, the
results of the present study are also in contrast to the
enhanced antinociceptive effects of a DOR agonist after
their co-administration with peripheral nitric oxide
synthases or cGMP-PKG pathway blockers in sciatic
nerve-injured animals [6]. Therefore, our findings
demonstrate that while MOR agonists use the same
mechanism of action to produce peripheral antinocicep-
tion during inflammatory and neuropathic pain with dif-
ferent effectiveness, DOR agonists did not active the
same way to produce peripheral antinociception in both
types of pain, although a comparable potency was main-
tained [2,6]. Thus, a possible explanation for the
reduced effectiveness of locally administered MOR ago-
nists during neuropathic pain as compared to inflamma-
tory, apart from the different alterations in the
expression of MOR that occurs after peripheral inflam-
mation (increases) or nerve injury (decreases) [2], might
be also related to the drastic reduction in the peripheral
KATP channels described in nerve-injured animals [20].
Several studies have demonstrated the involvement of
nitric oxide in the regulation of opioid receptor gene
transcription after peripheral inflammation and nerve
injury [6,21,22]. In this report, we have investigated the
role played by nitric oxide, synthesized by NOS1 and
NOS2, in the decreased expression of MOR after neuro-
pathic pain by using knockout mice for these enzymes.
Our results showed that, although the basal dorsal root
ganglia mRNA and protein levels of MOR were similar
between WT and NOS-KO animals, nerve injury only
decreased the MOR expression in WT mice. These find-
ings suggest that nitric oxide, derived from NOS1 and
NOS2, is implicated in the peripheral down-regulation
of MOR after sciatic nerve-injury. Therefore and accord-
ing to what occurs with the peripheral actions of mor-
phine during inflammatory and neuropathic pain, these
molecular data also support the evidence of the dual
role played by nitric oxide in the modulation of the
expression of MOR in both pain models. That is, while
nitric oxide increases the peripheral expression of MOR
during inflammation, it decreases their expression after
nerve injury.
In summary, our data demonstrate that the activation
of the nitric oxide-cGMP-PKG-KATP signaling periph-
eral pathway participates in the local antiallodynic
effects produced by morphine during sciatic nerve injury
and that nitric oxide, synthesized by NOS1 and NOS2,
is involved in the decreased expression of MOR during
neuropathic pain.
Conclusions
The present study demonstrates for first time that mor-
phine can effectively attenuate neuropathic pain through
the activation of the peripheral nitric oxide-cGMP-PKG-
KATP signaling pathway and the decreased expression
of MOR after sciatic nerve injury is regulated by nitric
oxide. These data contribute to a better comprehension
of the mechanism through peripheral MOR agonists
produce antinociception after nerve injury and provide
new insights into the development of novel therapeutic
approaches for alleviating neuropathic pain.
Methods
Animals
Male NOS1-KO (C57BL/6J background) and NOS2-KO
mice (C57BL/6J background) were purchased from Jack-
son Laboratories (Bar Harbor, ME, USA) while WT
mice with the same genetic background (C57BL/6J)
were acquired from Harlan Laboratories (Barcelona,
Spain). All mice weighing 21 to 25 g were housed under
12-h/12-h light/dark conditions in a room with con-
trolled temperature (22°C) and humidity (66%). Animals
had free access to food and water and were used after a
minimum of 6 days acclimatization to the housing
conditions.
Animal procedures were conducted in accordance
with the guidelines of the UK Animals Act 1986 (Scien-
tific Procedures) and the guidelines of the European
Communities Directive 86/609/EEC regulating animal
research. The study protocol was approved by the local
Committee of Animal Use and Care of the Autonomous
University of Barcelona. All experiments were performed
under blind conditions.
Induction of neuropathic pain
Neuropathic pain was induced by the chronic constric-
tion of the sciatic nerve [6,8]. Briefly, sciatic nerve liga-
tion was performed under isoflurane anesthesia (3%
induction, 2% maintenance). The biceps femoris and the
gluteus superficialis were separated by blunt dissection,
and the right sciatic nerve was exposed. The injury was
produced by tying three ligatures around the sciatic
nerve as described by Bennett and Xie [23]. The ligatures
(4/0 silk) were tied loosely around the nerve with 1 mm
spacing, until they elicited a brief twitch in the respective
hindlimb, which prevented over-tightening of the liga-
tions, taking care to preserve epineural circulation.
Sham-operated mice that underwent exposure of the
right sciatic nerve without ligature were used as controls.
The development of mechanical and thermal allodynia
was evaluated by using the von Frey filaments and cold
plate tests, respectively. All animals were tested in each
paradigm before surgery and at 21 days after CCI.
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Nociceptive behavioral tests
Mechanical allodynia was quantified by measuring the
hind paw withdrawal response to von Frey filament sti-
mulation. In brief, animals were placed in a Plexiglas®
box (20 cm high, 9 cm diameter) with a wire grid bot-
tom through which the von Frey filaments (North Coast
Medical, Inc., San Jose, CA, USA) bending force range
from 0.008 to 3.5 g, were applied by using a modified
version of the up-down paradigm, as previously reported
by Chaplan [24]. The filament of 0.4 g was used first
and the 3.5 g filament was used as a cut-off. Then, the
strength of the next filament was decreased or increased
according to the response. The threshold of response
was calculated from the sequence of filament strength
used during the up-down procedure by using an Excel
program (Microsoft Iberia SRL, Barcelona, Spain) that
includes curve fitting of the data. Clear paw withdrawal,
shaking or licking of the paw were considered nocicep-
tive-like responses. Both ipsilateral and contralateral
hind paws were tested. Animals were allowed to habitu-
ate for 1 h before drug administration in order to allow
an appropriate behavioral immobility.
Thermal allodynia to cold stimulus was assessed by
using the hot/cold-plate analgesia meter (Ugo Basile,
Italy), previously described by Bennett and Xie [23]. The
number of elevations of each hind paw was recorded in
the mice exposed to the cold plate (4 ± 0.5°C) for 5
minutes.
Molecular experiments
Tissue isolation
Sham-operated and sciatic nerve-injured WT, NOS1-KO
and NOS2-KO mice were sacrificed at 21 days after sur-
gery by cervical dislocation. Three dorsal root ganglia
from the ipsilateral lumbar section (L3 to L5) were col-
lected from each animal. They were removed immedi-
ately after sacrifice, frozen in liquid nitrogen and stored
at -80°C until assay. Because of the small size of the uni-
lateral dorsal root ganglia, tissues from three to five ani-
mals were pooled together to obtain enough RNA or
protein levels for performing the real time-PCR or Wes-
tern blot analysis, respectively.
Total RNA extraction and reverse transcription
Tissues were homogenized in ice-cold with a homogeni-
zer (Ultra-Turf, T8; Ika Werke, Staufen, Germany) and
the total RNA was extracted with TRIzol reagent (Invi-
trogen, Renfrewshire, England). The amount of the puri-
fied RNA (A260/A280 ratio ≥ 1.9) was determined by
spectrophotometry. In all experiments, 1 μg of total
RNA was reverse transcribed into cDNA using Super-
Script II RNAse H- reverse transcriptase (Invitrogen,
Renfrewshire, UK) in a final volume of 10 μl. Negative
controls were performed in which all of the components
were included except reverse transcriptase.
TaqMan probe real-time polymerase chain reaction (PCR)
The expression of MOR mRNA was determined by real-
time PCR using a designed mice TaqMan® gene expres-
sion assay (Applied Biosystems, CA, USA) for this gene
(MU-OR1-E2E3). A probe against GAPDH (Mm
99999915_g1) was used as endogenous control and reac-
tions without RNA were included as negative controls to
ensure the specificity. PCR reactions were set up in 96-
well plates containing the corresponding cDNA, 0.9
μmol/L of each forward and reverse primers, 0.25 μmol/
L of TaqMan® MGB probe and a final concentration of
1× universal master mix (Applied Biosystems, CA,
USA), which provides the PCR buffer, MgCl2, dNTPs,
and the thermal stable AmpliTaq Gold DNA polymer-
ase. The assay was conducted using the Applied Biosys-
tems ABI PRISM 7000 Sequence Detection System. All
samples were assayed in duplicate. Relative expression
of the target gene was calculated by means of the com-
parative threshold cycle (CT) method [25].
Western blot analysis
The MOR protein levels were analyzed by Western blot.
Tissues were homogenized in ice-cold lysis buffer (50
mM Tris·Base, 150 nM NaCl, 1% NP-40, 2 mM EDTA,
1 mM phenylmethylsulfonyl fluoride, 0.5 Triton X-100,
0.1% SDS, 1 mM Na3VO4, 25 mM NaF, 0.5% protease
inhibitor cocktail, 1% phosphatase inhibitor cocktail). All
reagents were purchased at Sigma (St. Louis, MO, USA)
with the exception of NP-40 from Calbiochem. The
crude homogenate was solubilised 1 hour at 4°C, soni-
cated for 10 seconds and centrifugated at 4°C for 15
min at 700 × g. The supernatants (80 μg of total pro-
tein) were mixed with 4 × laemmli loading buffer and
then loaded onto 4% stacking/10% separating SDS-poly-
acrylamide gels. The proteins were electrophoretically
transferred onto PVDF membrane for 90 minutes,
blocked with PBST + 5% nonfat dry milk, and subse-
quently incubated overnight at 4°C with a polyclonal
rabbit anti-MOR antibody (1:1.000, Chemicon, Milli-
pore). The proteins were detected by a horseradish per-
oxidase-conjugated anti-rabbit secondary antibody (GE
Healthcare, Little Chalfont, Buckinghamshire, UK) and
visualized by chemiluminescence reagents provided with
the ECL kit (Amersham Pharmacia Biotech, Piscataway,
NJ, USA) and exposure onto hyperfilm (GE, Healthcare).
The intensity of blots was quantified by densitometry.
The membrane was stripped and reapplied with a
monoclonal rabbit anti-b-actin antibody (1:10.000,
Sigma, St. Louis, MO, USA) used as a loading control.
Experimental protocol
In a first set of experiments we assessed the expression
of neuropathic pain by using the mouse model of CCI
previously used by us [6,8]. After the habituation period,
baseline responses were established in the following
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sequence: von Frey filaments and cold plate tests. After
that, neuropathic pain was induced and animals were
again tested in each paradigm at 21 days after surgery
before and after drug administration. Sham-operated
mice were used as controls.
Due to the lack of mechanical and thermal allodynia
induced by CCI in NOS1-KO and NOS2-KO mice, as
we have previously demonstrated [8], the mechanical
and thermal antiallodynic effects produced by the sub-
plantar administration of different doses of morphine
(133-400 nmol) or saline in the ipsilateral and contralat-
eral paws of sciatic nerve-injured and sham-operated
animals, were only evaluated in WT mice.
In another set of experiments, the specificity of the
mechanical and thermal antiallodynic effects produced
by a high dose of morphine (400 nmol) in sciatic nerve-
injured WT mice at 21 days after surgery, was assessed
by evaluating the reversibility of their effects with the
peripheral co-administration with a selective MOR
antagonist (CTAP; 108.7 nmol) or a peripheral non-
selective opioid receptor antagonist (NX-ME; 42.6
nmol). The effects of these antagonists administered
alone were also tested in sciatic nerve-injured and
sham-operated WT mice at 21 days after surgery.
The possible involvement of the peripheral nitric
oxide-cGMP-PKG- KATP signaling pathway, activated
by NOS1 and NOS2, in the local mechanical and ther-
mal antiallodynic effects of a MOR agonist has been
evaluated in an extra group of WT mice. For this pur-
pose, the local effects produced by different doses of
NANT (17.0-50.9 nmol) a selective NOS1 inhibitor [26],
L-NIL (44.7-134.1 nmol) a selective NOS2 inhibitor
[27], ODQ (4.0-13.3 nmol) a selective soluble guanylyl
cyclase inhibitor [28], Rp-8-pCPT-cGMPs (1.2-4.1 nmol)
a PKG inhibitor [29], glibenclamide (20.2-60.7 nmol) a
KATP channel blocker [30] or vehicle administered
alone or combined with a high dose of morphine (400
nmol) in the ipsilateral and contralateral paws of sciatic
nerve-injured and sham-operated WT mice at 21 days
after surgery, were also evaluated. The doses of all tested
inhibitors were selected according to our previous
experiments as the ones which did not produce a signif-
icant antiallodynic effect after CCI-induced neuropathic
pain [6].
In all experiments, antinociception in Von Frey fila-
ments is expressed as the percentage of maximal possi-
ble effect, where the test latencies pre (baseline) and
post drug administration are compared and calculated
according to the following equation:
Percentage maximal possible effect = [
(
drug − baseline) / (cut − off− baseline)]×100
In the cold plate test, the inhibitory effects were calcu-
lated according to the following equation:
Percentage inhibition = [
(
paw elevations number at baseline − paw elevations number after drug) /
paw elevations number at baseline]× 100.
Finally, the mRNA and protein levels of MOR in the
ipsilateral site of the dorsal root ganglia from sciatic
nerve-injured or sham-operated WT, NOS1-KO and
NOS2-KO mice at 21 after surgery were also evaluated
by using real time PCR and western blot, respectively.
Drugs
Morphine-HCl was obtained from Alcaiber S.A.
(Madrid, Spain) and L-NIL from Tocris (Ellisville, MI).
CTAP, NX-ME, NANT, ODQ, Rp-8-pCPT-cGMPs and
glibenclamide were purchase from Sigma-Aldrich (St.
Louis, MO). Morphine, CTAP, NX-ME, NANT, L-NIL
and Rp-8-pCPT-cGMPs were dissolved in saline solu-
tion (0.9% NaCl) while ODQ and glibenclamide in
dimethyl sulfoxide (DMSO; 10% and 50% solution in
saline, respectively). All drug combinations were diluted
in the highest required concentration of DMSO. All
drugs alone or combined were injected in a final volume
of 30 μl. In all experiments, drugs were administered
into the plantar side of the right paw, 20 min before
behavioral testing. For each group treated with a drug
the respective control group received the same volume
of vehicle.
Statistical analysis
Data are expressed as mean ± standard error of the
mean (SEM). For each test and dose, the comparison of
the effects produced by morphine vs. the effects pro-
duced by vehicle in the contralateral and ipsilateral paw
of nerve-injured or sham-operated mice was evaluated
by using a Student’s t test. The ED50 values (dose that
produced a 50% of the maximal effect) plus 95% confi-
dence limits were determined by linear regression analy-
sis of dose-response relations based on at least 5-6 mice
per dose.
For each test, the reversion of the mechanical and
thermal antiallodynic effects produced by morphine
with CTAP or NX-ME and the effects produced by
these antagonists administered alone in the ipsilateral
paw of sciatic nerve-injured and sham operated WT
mice were analyzed by using a one way ANOVA fol-
lowed by the Student Newman Keuls test.
The comparison between the mechanical and thermal
antiallodynic effects produced by a high dose of mor-
phine subplantarly administered alone or combined with
different doses of specific inhibitors (NANT, L-NIL,
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ODQ, Rp-8-pCPT-cGMPs or glibenclamide) in the ipsi-
lateral paw of sciatic nerve-injured and sham-operated
WT mice was performed by using a one way ANOVA
followed by the Student Newman Keuls test.
Changes in the expression of MOR (mRNA or pro-
tein) in the dorsal root ganglia of sciatic nerve-injured
and sham-operated WT, NOS1-KO and NOS2-KO mice
at 21 after surgery, were analyzed by using a two-way
ANOVA (genotype and surgery as between factors of
variation), followed by the corresponding one way
ANOVA or Student’s t test when required. A value of P
<0.05 was considered as a significant.
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